{"id":934584,"date":"2026-02-05T14:21:22","date_gmt":"2026-02-05T19:21:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/"},"modified":"2026-02-05T14:21:22","modified_gmt":"2026-02-05T19:21:22","slug":"allogene-therapeutics-announces-participation-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/","title":{"rendered":"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SOUTH SAN FRANCISCO, Calif., Feb.  05, 2026  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026.<\/p>\n<p>Citi&#8217;s 2026 Virtual Oncology Leadership Summit<br \/>Wednesday, February 18<br \/>9:15AM PT\/12:15PM ET<\/p>\n<p>TD Cowen 46th Annual Health Care Conference <br \/>Tuesday, March 3<br \/>8:50AM PT\/11:50AM ET<\/p>\n<p>Any available webcasts will be posted to the Company&#8217;s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MeEjAxV3w6HWBS3Y-khm7ctVQLUr1qN4D9ZMR5zhRGkb4LzMbT1fFnuM9hLTqFeSrcxsDY6H5r2WAJ83nhQWplvXNdjkiDTDV5o4raMRPrA=\" rel=\"nofollow\" target=\"_blank\">www.allogene.com<\/a> under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company&#8217;s website for approximately 30 days.<\/p>\n<p>\n        <strong>About\u00a0Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MeEjAxV3w6HWBS3Y-khm7YEqh9_iofsq_OHDRQdW9MY8PIPYcgWahNe0_ZdsPYqctkZcfYMWtS0dLnDWpl5GAmdmFmI19HG45aVSosRoIcM=\" rel=\"nofollow\" target=\"_blank\">www.allogene.com<\/a>, and follow Allogene Therapeutics on X and LinkedIn.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements for Allogene<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene\u2019s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene\u2019s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene\u2019s filings with the\u00a0SEC, including without limitation under the \u201cRisk Factors\u201d heading in its Quarterly Report on Form 10-Q for the quarter ended\u00a0September 30, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>EVP, Chief Corporate Affairs &amp; Brand Strategy Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JqMstVBkAlg7jba0oTAvo7ZIREoqzg6ALZI_rE8uaFnbzlRvdF6Z7DBwuyDHm4pi94RRX7FDExvyT_ZsBejQqi13M-yACoWzN1Lr2othSrSDi2QQX1rJ74rhTvyKySbv\" rel=\"nofollow\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTI5YTVmMDgtODY2MS00NmMxLTkxMzgtNGFmZjQ2MjkyZDk0LTExMzU4MTgtMjAyNi0wMi0wNS1lbg==\/tiny\/Allogene-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026. Citi&#8217;s 2026 Virtual Oncology Leadership SummitWednesday, February 189:15AM PT\/12:15PM ET TD Cowen 46th Annual Health Care Conference Tuesday, March 38:50AM PT\/11:50AM ET Any available webcasts will be posted to the Company&#8217;s website at\u00a0www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company&#8217;s website for approximately 30 days. About\u00a0Allogene Therapeutics Allogene Therapeutics, with headquarters in South San &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics Announces Participation in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-934584","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026. Citi&#8217;s 2026 Virtual Oncology Leadership SummitWednesday, February 189:15AM PT\/12:15PM ET TD Cowen 46th Annual Health Care Conference Tuesday, March 38:50AM PT\/11:50AM ET Any available webcasts will be posted to the Company&#8217;s website at\u00a0www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company&#8217;s website for approximately 30 days. About\u00a0Allogene Therapeutics Allogene Therapeutics, with headquarters in South San &hellip; Continue reading &quot;Allogene Therapeutics Announces Participation in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T19:21:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences\",\"datePublished\":\"2026-02-05T19:21:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/\"},\"wordCount\":450,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/\",\"name\":\"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=\",\"datePublished\":\"2026-02-05T19:21:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in the first quarter of 2026. Citi&#8217;s 2026 Virtual Oncology Leadership SummitWednesday, February 189:15AM PT\/12:15PM ET TD Cowen 46th Annual Health Care Conference Tuesday, March 38:50AM PT\/11:50AM ET Any available webcasts will be posted to the Company&#8217;s website at\u00a0www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company&#8217;s website for approximately 30 days. About\u00a0Allogene Therapeutics Allogene Therapeutics, with headquarters in South San &hellip; Continue reading \"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-05T19:21:22+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences","datePublished":"2026-02-05T19:21:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/"},"wordCount":450,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/","name":"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=","datePublished":"2026-02-05T19:21:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0Mzk0MiM3Mzk1MTA3IzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics Announces Participation in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=934584"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/934584\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=934584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=934584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=934584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}